These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32460887)

  • 1. Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome.
    Niessen FA; van Mourik MSM; Bruns AHW; Raijmakers RAP; de Groot MCH; van der Bruggen T
    Antimicrob Resist Infect Control; 2020 May; 9(1):74. PubMed ID: 32460887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study.
    Paret R; Le Bourgeois A; Guillerm G; Tessoulin B; Rezig S; Gastinne T; Couturier MA; Boutoille D; Lecomte R; Ader F; Le Gouill S; Ansart S; Talarmin JP; Gaborit B
    J Antimicrob Chemother; 2022 Aug; 77(9):2546-2556. PubMed ID: 35748614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance of empirical antimicrobial therapy by surveillance cultures in high-risk neutropenic patients: a retrospective cohort study.
    de la Court JR; Heijmans J; Huynh J; Sieswerda E; de Jonge NA; van Dijk K; Sigaloff KCE; Schade RP
    Antimicrob Resist Infect Control; 2022 Dec; 11(1):160. PubMed ID: 36529742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of early de-escalation of empiric antimicrobial therapy in acute leukemia patients with febrile neutropenia at a large academic medical center.
    Ly WJ; Brown EE; Pedretti Z; Auten J; Wilson WS
    J Oncol Pharm Pract; 2023 Mar; 29(2):305-310. PubMed ID: 34927495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
    Metan G; Kaynar L; Yozgat N; Elmali F; Kürkçüoglu CA; Alp E; Çetin M
    Infez Med; 2017 Mar; 25(1):33-37. PubMed ID: 28353453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in vancomycin-resistant Enterococcus colonization associated with a reduction in carbapenem use as empiric therapy for febrile neutropenia in patients with acute leukemia.
    Ford CD; Coombs J; Stofer MG; Lopansri BK; Webb BJ; Ostronoff F; Asch J; Hoda D
    Infect Control Hosp Epidemiol; 2019 Jul; 40(7):774-779. PubMed ID: 31046849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial.
    de Jonge NA; Sikkens JJ; Zweegman S; Beeker A; Ypma P; Herbers AH; Vasmel W; de Kreuk A; Coenen JLLM; Lissenberg-Witte B; Kramer MHH; van Agtmael MA; Janssen JJWM
    Lancet Haematol; 2022 Aug; 9(8):e563-e572. PubMed ID: 35691326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial Stewardship in a Hematological Malignancy Unit: Carbapenem Reduction and Decreased Vancomycin-Resistant Enterococcus Infection.
    Webb BJ; Majers J; Healy R; Jones PB; Butler AM; Snow G; Forsyth S; Lopansri BK; Ford CD; Hoda D
    Clin Infect Dis; 2020 Aug; 71(4):960-967. PubMed ID: 31751470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of an antimicrobial stewardship intervention for early adaptation of antibiotic therapy in high-risk neutropenic patients.
    Durand C; Risso K; Loschi M; Retur N; Emery A; Courjon J; Cluzeau T; Carles M
    Antimicrob Resist Infect Control; 2024 Jan; 13(1):5. PubMed ID: 38233960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical?
    Micol JB; Chahine C; Woerther PL; Ghez D; Netzer F; Dufour C; Merad M; Blot F; Chachaty E; de Botton S; Gachot B
    Clin Microbiol Infect; 2014 Jul; 20(7):O453-5. PubMed ID: 24313354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of empirical antibiotic therapy discontinuing for fever of unknown origin during high-risk neutropenia in children.
    Clément L; Hélène D; Maud M; Chrystelle D; Constance B; Fréderic M; France R; Pilar GM; José-Miguel TD; Blandine R
    J Infect; 2024 Jun; 88(6):106171. PubMed ID: 38697268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
    Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
    Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
    Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
    BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients.
    Snyder M; Pasikhova Y; Baluch A
    Cancer Control; 2021; 28():10732748211045593. PubMed ID: 34558349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
    Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
    Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of repeat blood cultures during febrile neutropenia in adult acute myeloid leukaemia patients undergoing intensive chemotherapy.
    Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Akahoshi Y; Harada N; Ugai T; Kusuda M; Kameda K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Tanihara A; Kanda Y
    Infect Dis (Lond); 2017 Oct; 49(10):748-757. PubMed ID: 28631944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low utilization of vancomycin in febrile neutropenia: real-world evidence from 4 Brazilian centers.
    Ramos JF; Pereira AD; Seiwald MCN; Gandolpho LS; Molla VC; Guaraná M; Nouér SA; Nucci M; Rodrigues CA
    Support Care Cancer; 2023 Nov; 31(12):687. PubMed ID: 37947888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
    Ghosh S; Chakraborty M; Samanta S; Sinha N; Saha S; Chattopadhyay A; Roy SS; Bhattacharyya M
    Ann Hematol; 2021 Feb; 100(2):395-403. PubMed ID: 33140134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort.
    Van de Wyngaert Z; Berthon C; Debarri H; Bories C; Bonnet S; Nudel M; Carpentier B; Legrand C; Barbieux S; Chauvet P; Simonnet A; Willaume A; Bossard JB; Renaud L; Wattebled KJ; Escure G; Branche N; Arib I; Titecat M; Quesnel B; Alfandari S
    Int J Antimicrob Agents; 2019 Jun; 53(6):781-788. PubMed ID: 30831232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.